32.99 USD
▼-0.15-0.45%
盘后 33.00 +0.03%
2026-09-15
市值
$2.06B
市盈率
—
EPS
-4.18
股息率
—
52 周区间
9.10 – 47.84
成交量
819.59K
Beta
2.18
目标价
69.60
52W 低 9.1052W 高 47.84
价格走势
公司简介
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac...